Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia
Background As a malignancy of hematopoietic origin, the standard-of-care cytoreductive chemotherapy can not provide satisfactory treatment effect for patients with acute myeloid leukemia (AML). Immunotherapy has received increasing attention in leukemia treatment. However, the immunosuppressive micr...
Saved in:
Main Authors: | Jing Yang, Ling Zhang, Nan Wu, Jiayuan Hu, Jun Ren, Xinyi Chen, Xingyu Wei, Minghui Sun, Ziwei Li, Yongcan Liu, Yan Shu, Genyou Li, Fangfang Jin, Can Lin, Lisha Tang, Zesong Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/7/e011148.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Doxing: The Sandy Hook Case Study
by: Daria Bulgakova
Published: (2025-01-01) -
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01) -
Строение гидратного слоя поверхности композитных систем SiO<sub>2</sub>/ДНК(Dox) и SiO<sub>2</sub>/ДНК(Dox)/фуллерен С<sub>60</sub>
by: V. V. Turov, et al.
Published: (2011-05-01) -
Prognostic significance of CD204 and IDO1 expression in esophageal tumors
by: O. V. Kovaleva, et al.
Published: (2021-07-01) -
Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab.
by: Dagmar von Bubnoff, et al.
Published: (2025-01-01)